September 10, 2018
1 min read
Save

Smartphone photoscreening app for amblyopia consistent with screening technology

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Smartphone photoscreening for amblyopia in pediatric patients using the GoCheck Kids application had positive predictive value comparable with other commercial objective screeners.

Ten pediatricians in four practices used Nokia 1020 smartphones with single-axis Gobiquity software. The pediatricians completed 6,310 in-office screenings, resulting in a referral rate of 5%; 25% were referred for high anisometropia, 31% for hyperopia and 15% for myopia.

Of the 332 patients who did not pass the screening and were referred, 217 (65%) were followed up by the study authors.

“The [positive predictive value] from GoCheck Kids is favorably comparable to the excellent predictive value attained by our other pediatric colleagues who utilize Plusoptix, SPOT and iScreen devices. All the current devices, including GoCheck Kids, used early (age 12 to 60 months) are a very effective weapon in our war against amblyopia blindness. Make sure your specific early photoscreening is followed up by reliable acuity screening (kindergarten exit through third grade) with monocularity assured by adhesive patch over the non-tested eye,” study co-author Robert W. Arnold, MD, FAAP, told Healio.com/OSN.

Of the 217 follow-up exams, the positive predictive value was 68% by 2013 age-stratified standards and 77% by 2003 American Association for Pediatric Ophthalmology and Strabismus standards. – by Robert Linnehan

Disclosures: Arnold reports he is a non-paid member of the medical advisory board for Gobiquity and a board member of Glacier Medical Software, which markets neonatal

intensive care unit cloud-based vision monitoring software ROP Check. Please see the study for all other authors’ relevant financial disclosures.